Autres langues Eurofins Scientific SE

Actions

ERF

FR0014000MR3

Recherche biotechnologique et médicale

Temps réel Euronext Paris 11:38:55 27/08/2026			Varia. 5j.	Varia. 1 janv.
72,56 ^EUR	-0,36%		-0,33%	+16,31%

26/08	L'Europe termine en hausse... et les regards se tournent vers l'Amérique
24/08	Avis d'analystes du jour : avis positifs sur ArcelorMittal, Eurofins et Unibail

Autres langues

26/08	Lotus Bakeries, la galleta más cara de la bolsa europea
24/08	Eurofins: Weekly Report on Share Repurchases From 17th August to 21st August 2026
24/08	Eurofins Scientific SE: Director/PDMR Shareholding
24/08	Afternoon Meeting: El triple examen de Wall Street
24/08	Wall Street's Three-Way Stress Test
19/08	Eurofins Scientific: Director/PDMR Shareholding
18/08	Eurofins Scientific SE: Weekly Report on Share Repurchases from 10th August to 14th August 2026
14/08	Eurofins Scientific: Director/PDMR Shareholding
13/08	Eurofins CDMO Alphora Expands Kilolab and High Potency Development and Manufacturing Capabilities
12/08	Eurofins Scientific: Director/PDMR Shareholding
10/08	Eurofins Scientific SE: Weekly Report on Share Repurchases from 03rd August to 07th August 2026
07/08	Eurofins Scientific: Director/PDMR Shareholding
04/08	Eurofins Scientific: Director/PDMR Shareholding
03/08	Eurofins: Weekly Report on Share Repurchases From 27th July to 31st July 2026
03/08	Eurofins Scientific SE: Director/PDMR Shareholding
31/07	Eurofins Scientific: Director/PDMR Shareholding
29/07	Eurofins Scientific: Director/PDMR Shareholding
27/07	Eurofins: Weekly Report on Share Repurchases From 20th July to 24th July 2026
24/07	Eurofins Scientific: Director/PDMR Shareholding
24/07	Unternehmenskalender vom 27. bis 31. Juli 2026
23/07	Eurofins Scientific : BioPharma's slowdown raises questions on 2026 organic growth target
23/07	Eurofins Scientific Se Seeks Acquisitions
23/07	Tranche Update on Eurofins Scientific SE's Equity Buyback Plan announced on April 25, 2025.
23/07	Notenbanken werden von der Inflation auf dem falschen Fuß erwischt
23/07	Eurofins Makes Significant Progress in H1 2026 Towards Its Mid-Term 2027 Objectives, With 130bps of Adjusted EBITDA Margin Expansion, Strong Cash Conversion, and 29% EPS Growth